deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03459443

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471

Sponsor: Alexion Pharmaceuticals, Inc.

Interventions Danicopan
Updated 19 times since 2018 Last updated: Aug 17, 2023 Started: Jun 20, 2018 Primary completion: Mar 29, 2021 Completion: Mar 29, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The reason for terminating study early was inconclusive efficacy results. No safety findings were identified.

Listed as NCT03459443, this PHASE2 trial focuses on C3 Glomerulonephritis and C3 Glomerulopathy and remains terminated or withdrawn. Sponsored by Alexion Pharmaceuticals, Inc., it has been updated 19 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Feb 2019 · 5 months · monthly snapshot~Feb 2019 – ~Oct 2019 · 8 months · monthly snapshot~Oct 2019 – ~May 2020 · 7 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Apr 2022 · 5 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

19 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Dec 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Sep 2023 — Dec 2023 [monthly]

    Terminated PHASE2

Show 14 earlier versions
  1. Apr 2023 — Sep 2023 [monthly]

    Terminated PHASE2

  2. Sep 2022 — Apr 2023 [monthly]

    Terminated PHASE2

    Status: CompletedTerminated

  3. Apr 2022 — Sep 2022 [monthly]

    Completed PHASE2

  4. Nov 2021 — Apr 2022 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  5. Jan 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  7. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

  8. Oct 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  9. Feb 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  10. Sep 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  11. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  12. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  13. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  14. Mar 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alexion Pharmaceuticals, Inc.
Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .